Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $1.3 billion.

  • Collegium Pharmaceutical's Total Liabilities fell 487.95% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 487.95%. This contributed to the annual value of $1.4 billion for FY2024, which is 5136.45% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Total Liabilities of $1.3 billion as of Q3 2025, which was down 487.95% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Total Liabilities ranged from a high of $1.4 billion in Q4 2024 and a low of $460.7 million during Q2 2021
  • Moreover, its 5-year median value for Total Liabilities was $1.0 billion (2022), whereas its average is $981.4 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 12748.7% in 2022, then plummeted by 1740.21% in 2024.
  • Collegium Pharmaceutical's Total Liabilities (Quarter) stood at $489.1 million in 2021, then surged by 100.2% to $979.3 million in 2022, then dropped by 3.21% to $947.9 million in 2023, then surged by 51.36% to $1.4 billion in 2024, then dropped by 7.13% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.4 billion during Q1 2025.